Biochemical and clinical significance of the posttreatment prostate-specific antigen bounce for prostate cancer patients treated with external beam radiation therapy alone Presented at the 46th Annual Meeting of the American Society for Therapeutic Radiology and Oncology, Atlanta, GA, October 3–7, 2004.

Show simple item record

dc.contributor.author Horwitz, Eric M. en_US
dc.contributor.author Levy, Lawrence B. en_US
dc.contributor.author Thames, Howard D. en_US
dc.contributor.author Kupelian, Patrick A. en_US
dc.contributor.author Martinez, Alvaro A. en_US
dc.contributor.author Michalski, Jeffrey M. en_US
dc.contributor.author Pisansky, Thomas M. en_US
dc.contributor.author Sandler, Howard M. en_US
dc.contributor.author Shipley, William U. en_US
dc.contributor.author Zelefsky, Michael J. en_US
dc.contributor.author Zietman, Anthony L. en_US
dc.contributor.author Kuban, Deborah A. en_US
dc.date.accessioned 2007-09-20T17:41:00Z
dc.date.available 2008-01-03T16:19:17Z en_US
dc.date.issued 2006-10-01 en_US
dc.identifier.citation Horwitz, Eric M.; Levy, Lawrence B.; Thames, Howard D.; Kupelian, Patrick A.; Martinez, Alvaro A.; Michalski, Jeffrey M.; Pisansky, Thomas M.; Sandler, Howard M.; Shipley, William U.; Zelefsky, Michael J.; Zietman, Anthony L.; Kuban, Deborah A. (2006). "Biochemical and clinical significance of the posttreatment prostate-specific antigen bounce for prostate cancer patients treated with external beam radiation therapy alone Presented at the 46th Annual Meeting of the American Society for Therapeutic Radiology and Oncology, Atlanta, GA, October 3–7, 2004. ." Cancer 107(7): 1496-1502. <http://hdl.handle.net/2027.42/55827> en_US
dc.identifier.issn 0008-543X en_US
dc.identifier.issn 1097-0142 en_US
dc.identifier.uri http://hdl.handle.net/2027.42/55827
dc.identifier.uri http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=16944536&dopt=citation en_US
dc.description.abstract BACKGROUND. The posttreatment prostate-specific antigen (PSA) bounce phenomenon has been recognized in at least 20% of all patients treated with radiation. The purpose of the current report was to determine if there was a difference in biochemical and clinical control between the bounce and nonbounce (NB) patients using pooled data on 4839 patients with T1-2 prostate cancer treated with external beam radiation therapy (RT) alone at 9 institutions between 1986 and 1995. METHODS. The median follow-up was 6.3 years. A posttreatment PSA bounce was defined by a minimal rise of 0.4 ng/mL over a 6-month follow-up period, followed by a drop in PSA level of any magnitude. Endpoints included no biochemical evidence of disease (bNED) failure (BF) (ASTRO definition), distant failure (DF), cause-specific failure (CSF), and overall survival (OS). Patients were stratified by pretreatment PSA, Gleason score, T stage, age, dose, and risk group. RESULTS. In all, 978 (20%) patients experienced at least 1 posttreatment PSA bounce. Within 3 subgroups (risk group, pretreatment PSA, and age), statistically significant differences of remaining bounce-free were observed on univariate analysis. Patients < 70 years had a 72% chance of remaining bounce-free at 5 years compared with 75% for older patients ( P = .04). The NB patients had 72% bNED control at 10 years compared with 58% for the bounce patients. The effect of a bounce remained statistically significant on multivariate analysis ( P < .0001). No statistically significant difference in DF, CSF, or OS was observed. CONCLUSIONS. Patients treated with external beam radiation therapy alone who experience a posttreatment PSA bounce have increased risk of BF. However, this did not translate into a difference in clinical failure with the available follow-up in the current study. Cancer 2006. © 2006 American Cancer Society. en_US
dc.format.extent 140956 bytes
dc.format.extent 3118 bytes
dc.format.mimetype application/pdf
dc.format.mimetype text/plain
dc.publisher Wiley Subscription Services, Inc., A Wiley Company en_US
dc.subject.other Life and Medical Sciences en_US
dc.subject.other Cancer Research, Oncology and Pathology en_US
dc.title Biochemical and clinical significance of the posttreatment prostate-specific antigen bounce for prostate cancer patients treated with external beam radiation therapy alone Presented at the 46th Annual Meeting of the American Society for Therapeutic Radiology and Oncology, Atlanta, GA, October 3–7, 2004. en_US
dc.type Article en_US
dc.rights.robots IndexNoFollow en_US
dc.subject.hlbsecondlevel Oncology and Hematology en_US
dc.subject.hlbsecondlevel Public Health en_US
dc.subject.hlbtoplevel Health Sciences en_US
dc.description.peerreviewed Peer Reviewed en_US
dc.contributor.affiliationum Department of Radiation Oncology, University of Michigan, Ann Arbor, Michigan en_US
dc.contributor.affiliationother Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania ; Fax: (215) 214-1629 ; Department of Radiation Oncology, Fox Chase Cancer Center, 333 Cottman Ave., Philadelphia, PA 19111-2497 en_US
dc.contributor.affiliationother Department of Biomathematics, University of Texas M. D. Anderson Cancer Center, Houston, Texas en_US
dc.contributor.affiliationother Department of Biomathematics, University of Texas M. D. Anderson Cancer Center, Houston, Texas en_US
dc.contributor.affiliationother Department of Radiation Oncology, Cleveland Clinic Foundation, Cleveland, Ohio en_US
dc.contributor.affiliationother Department of Radiation Oncology, William Beaumont Hospital, Royal Oak, Michigan en_US
dc.contributor.affiliationother Department of Radiation Oncology, Mallinckrodt Institute of Radiology, St. Louis, Missouri en_US
dc.contributor.affiliationother Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota en_US
dc.contributor.affiliationother Department of Radiation Oncology, Massachusetts General Hospital, Boston, Massachusetts en_US
dc.contributor.affiliationother Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, New York, New York en_US
dc.contributor.affiliationother Department of Radiation Oncology, Massachusetts General Hospital, Boston, Massachusetts en_US
dc.contributor.affiliationother Division of Radiation Oncology, University of Texas M. D. Anderson Cancer Center, Houston, Texas en_US
dc.identifier.pmid 16944536 en_US
dc.description.bitstreamurl http://deepblue.lib.umich.edu/bitstream/2027.42/55827/1/22183_ftp.pdf en_US
dc.identifier.doi http://dx.doi.org/10.1002/cncr.22183 en_US
dc.identifier.source Cancer en_US
dc.owningcollname Interdisciplinary and Peer-Reviewed
 Show simple item record

This item appears in the following Collection(s)


Search Deep Blue

Advanced Search

Browse by

My Account

Information

Coming Soon


MLibrary logo